title: Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
abstract: BACKGROUND
  Class III β-tubulin, Sox2, and Survivin play important roles in tumor survival and proliferation. However, the association of these three factors with clinicopathological characteristics, chemoresistance, and survival in patients with ovarian cancer remains controversial.
  
  
  METHODS
  We investigated the predictive value and correlation among the expression levels of Class III β-tubulin, Sox2, and Survivin in 110 patients with stage III ovarian epithelial cancer, including 58 patients who received taxane-based chemotherapy and 52 patients who received non-taxane-based chemotherapy. Expression of these three factors was immunohistochemically examined in 110 ovarian tumor tissues obtained from patients before chemotherapy.
  
  
  RESULTS
  The positive expression rates for Class III β-tubulin, Sox2, and Survivin in ovarian tumor tissues were 59.09 %, 61.82 % and 52.73 %, respectively. The expression of nuclear Survivin and Class III β-tubulin was consistent with that of Sox2 (p = 0.005 and 0.020, respectively). Positive expression of Class III β-tubulin, Sox2, and nuclear Survivin was significantly associated with chemoresistance to taxane-based chemotherapy (p = 0.006, 0.007, and 0.009, respectively), but not to non-taxane-based chemotherapy. Additionally, overexpression of Class III β-tubulin, Sox2, and nuclear Survivin predicted poor progression-free survival in patients receiving taxane-based chemotherapy (p = 0.032, 0.005, and 0.004, respectively).
  
  
  CONCLUSIONS
  These findings suggest that overexpression of Class III β-tubulin, Sox2, and nuclear Survivin might be predictive of taxane resistance and poor progression-free survival in patients with stage III ovarian epithelial cancer. Expression of these three factors may show positive correlations in these patients.
authors.affiliation: Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China. jintongdu@sina.cn.|Shandong Cancer Hospital, Shandong Academy of Medical Science, Ji'nan, Shandong, 250012, China. jintongdu@sina.cn.
authors.forename: Jintong
authors.initials: J
authors.lastname: Du
authors.affiliation: Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China. beili008@hotmail.com.
authors.forename: Bei
authors.initials: B
authors.lastname: Li
authors.affiliation: Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China. fyl1599@126.com.
authors.forename: Yingli
authors.initials: Y
authors.lastname: Fang
authors.affiliation: Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China. y.g.liu@163.com.
authors.forename: Yanguo
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China. 530623106@qq.com.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China. lijisheng@gmail.com.
authors.forename: Jisheng
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China. wenzhou25@sdu.edu.cn.
authors.forename: Wen
authors.initials: W
authors.lastname: Zhou
authors.affiliation: Department of Chemotherapy, Qilu Hospital of Shandong University, No. 107 Wenhuaxi road, Ji'nan, Shandong, 250012, China. xiuwenwang12@sdu.edu.cn.
authors.forename: Xiuwen
authors.initials: X
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D002467:Cell Nucleus / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism*; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D055748:SOXB1 Transcription Factors / Q000378:metabolism*; D000077022:Survivin; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use; D014404:Tubulin / Q000378:metabolism*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; C527782:SOX2 protein, human; D055748:SOXB1 Transcription Factors; D000077022:Survivin; C498585:TUBB3 protein, human; D043823:Taxoids; D014404:Tubulin